Expanded Access Program Evaluating SkinTE in the Treatment of Wagner 1 Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TEMPORARILY_NOT_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this EAP is to provide access to SkinTE® for patients with Wagner I Diabetic Foot Ulcers (DFUs). SkinTE® is an autologous investigational product created from a healthy full-thickness skin harvest. SkinTE is applied directly to the wound with the goal of promoting healing.

In addition to providing treatment, the program will collect safety and efficacy data. This data will help us understand the potential risks and benefits of SkinTE® when used in a real-world setting. PolarityBio® provides research funding to the study site to support data collection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SkinTE™ in the Treatment of Diabetic Foot Wounds

NCT03881254

Diabetic Foot Diabetic Foot Ulcer Ulcer Foot

COMPLETED NA

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

NCT06140303

Diabetic Foot

ACTIVE_NOT_RECRUITING PHASE3

Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

NCT05372809

Diabetic Foot

TERMINATED PHASE3

SkinTE® in the Treatment of Venous Leg Wounds

NCT03881267

Venous Leg Ulcer Venous Stasis Venous Stasis Ulcer

COMPLETED NA

Prospective, Multicenter, RCT of the Tenex Ultrasound System

NCT06137222

Diabetic Foot Ulcer

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DFU Neuropathic Diabetic Ulcer - Foot Diabetic Foot Disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SkinTE

SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityBio following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE contains multicellular aggregates that contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular aggregates have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Autologous Heterogeneous Skin Construct

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years of age
2. Subjects are medically optimized with a documented history of Type I or Type II Diabetes Mellitus requiring insulin and/or oral therapy.
3. Presence of a DFU Wagner 1 grade wound on any aspect of the foot, provided that if the malleolus is involved, not more than 50% of the wound is above the mid-point of the medial malleolus. Note: Index Ulcer must maintain Wagner grade 1 from screening to harvest procedure.
4. Index ulcer (i.e., current episode of ulceration) has been present for ≥ four weeks (≥ 28 days) prior to the initial screening visit.
5. If other wound(s) are present on the same foot, they must be more than 2 cm distant from the index ulcer.
6. Ulcer size between 1.0 cm² and 25 cm² post-debridement at screening and day of Harvest, which may occur 3 to 30 days after screening.
7. Adequate circulation to the affected foot documented by a dorsal transcutaneous oxygen measurement (TCOM) or skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) of ≥ 0.7 and ≤ 1.2 or Arterial Doppler with a minimum of biphasic flow or Toe Brachial Index (TBI) ≥ 0.75 using the affected study extremity within 30 days of the screening visit.
8. Index ulcer and/or index ulcer limb may have had prior infection(s), but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines PEDIS Grade level 1.
9. The subject can comply with study visits, wound management, and follow-up regimen.
10. The treating investigator has determined that no suitable alternative therapy is available to adequately address the patient's medical needs.
11. Based on the treating investigator's clinical judgment and the severity of the patient's condition, the patient has the potential to derive meaningful benefits from the use of SkinTE.
12. Females of childbearing potential must agree to use effective methods of contraception (birth control pills, barriers, or abstinence) (Screening through End of Study (EOS) and undergo pregnancy tests.
13. Negative pregnancy test for females of childbearing potential (e.g., not post- menopausal for at least one year or surgically sterile).
14. Properly obtained written informed consent.
15. Subjects who previously received SkinTE as part of a prior SkinTE-related trial may be considered for participation, provided a new index ulcer is selected for treatment on the contralateral limb and sponsor approval is granted.

Exclusion Criteria

1. Participation in another investigational drug or therapeutic device trial within 30 days prior to screening.
2. Use of prohibited medication(s) as defined in this protocol.
3. Presence of diabetes with poor metabolic control, defined as a documented historical HbA1c ≥12.0% within 90 days prior to screening.
4. Subjects with a history of more than two weeks of treatment with immunosuppressants (including systemic corticosteroids \> 10mg prednisone (or equivalent) daily dose), or cytotoxic chemotherapy prior to screening.
5. Index ulcer treated within 30 days of screening with prohibited treatment as defined in this protocol.
6. Subjects with presence of gangrene, unstable ischemia, or active Charcot's foot.
7. Subjects with recent lower extremity revascularization within ≤30 days of screening.
8. Based on the treating investigators clinical judgement there is no suspicion of malignancy in the index ulcer.
9. History of osteomyelitis, cellulitis, or other soft tissue infections involving the index ulcer within 30 days of screening.
10. Subjects with exposed internal fixation on the same limb as the index ulcer. \[Note: External fixation is allowed if deemed stable by principal investigator.\]
11. Active infection of the index ulcer (as defined by IDSA PEDIS Grade 1 guidelines) of the affected limb.
12. History of radiation therapy on the affected limb.
13. Subject is pregnant or breastfeeding.

Eligible Sex

ALL

Accepts Healthy Volunteers

No